Ignyte Bio

Executive Summary

Ignyte Bio is a Cambridge-based biotechnology company founded in 2021 that supplies well-characterized human immune cell products and custom development services to academic, biotech, and pharmaceutical researchers. Operating at the intersection of oncology and immunology, its catalog includes PBMCs, T cells, NK cells, and specialized products such as induced Regulatory T Cells (iTregs). By simplifying biosourcing, Ignyte Bio enables researchers to access high-quality, reproducible immune cells for preclinical studies, drug discovery, and translational research. The company's focus on quality and characterization positions it as a reliable partner in the competitive research reagent market. While still early-stage and privately held, Ignyte Bio's niche in immune cell supply taps into growing demand for cell-based assays and immunotherapies. Its success will depend on expanding its customer base, launching new products, and establishing partnerships to scale operations.

Upcoming Catalysts (preview)

• Q3 2026Launch of new immune cell products (e.g., gene-edited or disease-specific cells)60% success
• TBDStrategic partnership with a major pharma or CRO for custom cell supply40% success